Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery Juhong JiangYuanzhi LuFen Xia PRECLINICAL STUDIES 23 January 2017 Pages: 251 - 259
A truncated apoptin protein variant selectively kills cancer cells Santiago Ruiz-MartínezJessica CastroAntoni Benito PRECLINICAL STUDIES 24 January 2017 Pages: 260 - 268
Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study Naminatsu TakaharaHiroyuki IsayamaKazuhiko Koike PRECLINICAL STUDIES 26 January 2017 Pages: 269 - 276
State-dependent block of voltage-gated sodium channels by the casein-kinase 1 inhibitor IC261 Karl J. FöhrUwe KnippschildOliver Adolph PRECLINICAL STUDIES 06 February 2017 Pages: 277 - 289
A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors Christos E. KyriakopoulosAmy M. BradenKari B. Wisinski PHASE I STUDIES 21 December 2016 Pages: 290 - 297
First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors Andres ForeroJohanna C. BendellMichael L. Maitland PHASE I STUDIES 03 January 2017 Pages: 298 - 306
A first-in-human Phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumors Hirofumi MukaiTakahiro KogawaAko Hosono PHASE I STUDIES 04 January 2017 Pages: 307 - 314
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors Geoffrey I. ShapiroUlka N. VaishampayanHossein Borghaei PHASE I STUDIES Open access 09 January 2017 Pages: 315 - 323
First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors S. FuH. HirteJ. M. Stewart PHASE I STUDIES Open access 01 February 2017 Pages: 324 - 333
Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study Ravi SalgiaR. Waide WeaverDavid R. Spigel PHASE II STUDIES Open access 15 March 2017 Pages: 334 - 344
A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer M. ThomasP. SadjadianF. Schneller III PHASE II STUDIES Open access 16 March 2017 Pages: 345 - 358
Current achievements and future perspectives of metronomic chemotherapy Adriana RomitiRosa FalconePaolo Marchetti REVIEW 01 December 2016 Pages: 359 - 374
Metabolic carbonyl reduction of anthracyclines — role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents Kamil PiskaPaulina KoczurkiewiczElżbieta Pękala REVIEW Open access 10 March 2017 Pages: 375 - 385
Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials? Christos FountzilasSelena StuartDevalingam Mahalingam SHORT REPORT 19 January 2017 Pages: 386 - 391
Surveillance of protocol deviations in Japanese oncology registration trials: a single institute experience Shinsuke SasadaNobuko UshirozawaNoboru Yamamoto SHORT REPORT 01 February 2017 Pages: 392 - 396
Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors S. FuH. HirteJ. M. Stewart Erratum Open access 07 April 2017 Pages: 397 - 397